SERPINA1 Pi*MZ als unabhängiger Risikofaktor für die Entwicklung eines hepatozellulären Karzinoms bei Patient:innen mit chronisch fortgeschrittener Lebererkrankung

L Balcar(Medical University of Vienna), M Mandorfer(Medical University of Vienna), Paul Thöne(Medical University of Vienna), Natalia Dominik(National Hospital for Neurology and Neurosurgery), L Hartl(Medical University of Vienna), M Trauner(Medical University of Vienna), R Paternostro(Medical University of Vienna), Matthias Pinter(Medical University of Vienna), G Semmler(Medical University of Vienna), M Jachs(Medical University of Vienna), Gero Kramer(Memorial Sloan Kettering Cancer Center), Benedikt Hofer(Austrian Academy of Sciences), Albert Friedrich Stättermayer(Medical University of Vienna), T Reiberger(Christian Doppler Laboratory for Thermoelectricity), Christian Sebesta(Donauspital), Maria Schwarz(Universitätsklinik für Neurologie), B Scheiner(Medical University of Vienna), B Simbrunner(Medical University of Vienna)
Zeitschrift für Gastroenterologie
May 1, 2025
10.1055/s-0045-1809219
Cited by 0

Related Papers

NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
|European Urology|2017|644
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
|Journal of Hepatology|2021|309
Cancer and liver cirrhosis: implications on prognosis and management
|ESMO Open|2016|287